The Varian Halcyon linear accelerator is designed for faster treatment time and fewer treatment errors than conventional linear accelerators. Its increased gantry speed (4 rpm), dose rate (800 MU/min), and leaf speed (5 cm/s) reduce treatment time. The 2 multileaf collimator banks of 1 cm leaf width could cause planning difficulties, but utilizing many arcs could address this challenge. While 3 or more arcs are often avoided due to the increased treatment time, the Halcyon can deliver 5 arcs in under 3 minutes. For prostate and head-and-neck, we hypothesized plan quality would increase with increasing arcs without compromising treatment time. Fifteen prostate and fifteen head-and-neck previously treated patients were replanned to 78 and 66 Gy, respectively. A total of 150 volumetric modulated arc therapy (VMAT) plans, ranging from 1 to 5 arcs, were created to compare organ-at-risk (OAR) sparing, target coverage, homogeneity, and hotspot volume. Plans were normalized to the prescribed dose of 98% and 95% of the primary target volume for prostate and head-and-neck, respectively. All prostate 4-arc and 5-arc plans met MD Anderson Cancer Center (MDACC) constraints, while 86.7%, 20%, and 6.7% of the 1-arc, 2-arc, and 3-arc plans did not meet constraints, respectively. As the number of arcs increased, all OAR maximum doses decreased. All head-and-neck 5-arc plans met MDACC constraints, while 73.3%, 26.7%, 13.3%, and 6.7% of the 1-arc, 2-arc, 3-arc, and 4-arc plans did not meet constraints, respectively. The contralateral parotid mean dose and the spinal cord maximum dose decreased with increasing arcs. Homogeneity and conformity indices decreased when increasing from 1 to 5 arcs for both prostate and head-and-neck. Overall, homogeneity and conformity indices and OAR doses improved when using three or more arcs. Therefore, using at least 3 arcs for VMAT plans on the Halcyon will increase plan quality without compromising treatment time.
Copyright © 2018 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.